奈达铂联合多西他赛治疗晚期非小细胞肺癌临床疗效及其对于细胞免疫功能的影响

目的：研究奈达铂联合多西他赛治疗晚期非小细胞肺癌临床疗效及其对于细胞免疫功能的影响。方法：研究共对96例晚期非小细胞肺癌患者进行了研究,将入组患者随机分为观察组和对照组,每组48例,观察组接受奈达铂联合多西他赛治疗,对照组接受顺铂联合紫杉醇治疗。对照两组疗效,生存率、无疾病进展时间、T淋巴细胞亚群水平以及并发症的发生情况。结果：观察组的部分缓解（PR）率高于对照组,进展（PD）率低于对照组;对照组治疗后的NK、CD3^＋、以及CD4^＋/CD8^＋水平均低于治疗前,CD8^＋水平高于治疗前,差异均具有统计学意义（P〈0.05）;观察组的NK、CD3^＋、以及CD4^＋/CD8^＋水平均高于对照组,CD8^＋水平低于对照组,差异均具有统计学意义（P〈0.05）;观察组的1年生存率高于对照组,无疾病进展时间长于对照组。结论：奈达铂联合多西他赛治疗晚期非小细胞肺癌可以取得良好的疗效,且生存率高,无疾病进展时间长,而且对于患者细胞免疫功能影响较为轻微。

Clinical efficacy of Nedaplatin plus docetaxel therapy on advanced non-small cell lung cancer cells and its impact on immune function

Objective： To study clinical efficacy of nedaplatin docetaxel therapy on advanced nonsmall cell lung cancer cells and its impact on immune function. Methods： A total of 96 patients with advanced non-small cell lung cancer patients were studied, according to the principles of the randomized control group patients were divided into observation group （n=48） and control group （n=48）. The observation group was given nedaplatin docetaxel therapy, the control group patients was given cisplatin plus paclitaxel therapy. Efficacy, survival rate, length of non-progression, T lymphocyte subsets levels and complications were compared between the two groups. Results： Rate of PR in the observation group was significantly higher than that in the control group, while PD rate was lower. After treatment, NK, CD3^＋ , and CD4^＋/CD8^＋ levels were lower than that before treatment, but CD8^＋ levels were higher, differences were significant （P〈0.05）. NK, CD3^＋, and CD4^＋/CD8^＋ of the observation group were all higher than that of the control group, but CD8^＋ was lower, showing significant difference （P〈0.05）. The observation group showed higher 1-year survival rate and longer non-disease progression period. Conclusion： Nedaplatin plus docetaxel is effective on advanced non-small cell lung cancer with relatively minor impact on patients＇ immune function.